rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    QTRX
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Quanterix CEO Everett Cunningham steps down, Jim Gute named interim
      15h agoInvesting.comQTRX
      ALZAI Health Corp. Enters into MOU with Quanterix Corporation to Advance Early Alzheimer's Disease Identification
      Nov 13Yahoo FinanceQTRX
      Quanterix Corporation Q3 2026 Earnings Call Summary
      Nov 9Yahoo FinanceQTRX
      What Quanterix (QTRX) Said on Its Q3 Earnings Call
      Nov 9Yahoo FinanceQTRX
      Quanterix Q3 2026 slides: revenue decline narrows as AD diagnostics ramp
      Nov 9Investing.comQTRX
      Quanterix earnings missed by $0.03, revenue topped estimates
      Nov 9Investing.comQTRX
      Quanterix Q3 2026 Earnings Call Transcript
      Nov 9BenzingaQTRX
      Earnings call transcript: Quanterix posts Q3 2026 revenue beat, stock falls premarket
      Nov 9Investing.comQTRX
      Earnings to Watch: Quanterix Corp (QTRX) Q3 2026 -- GF Value Sees 187% Upside
      Nov 6Yahoo FinanceQTRX
      Quanterix To Report Third Quarter 2026 Financial Results on November 9, 2026
      Oct 28Yahoo FinanceQTRX
      Quanterix partner receives China approval for neurology tests
      Oct 7Investing.comQTRX
      ALZpath and Quanterix Expand Strategic Licensing Agreement to Advance Next Generation Alzheimer's Disease Biomarker Research

      ALZpath, Inc., a leader in blood test-based diagnostic solutions for Alzheimer's disease, today announced the expansion of its licensing agreement with Quanterix Corporation. The expanded agreement broadens the use of ALZpath's proprietary pTau217 antibody technology on Quanterix's Simoa® research platform, supporting continued innovation as the field advances toward increasingly precise blood-based approaches to understanding Alzheimer's disease pathology.

      Oct 7Yahoo FinanceQTRX
      Quanterix and Innovita Expand IVD Access in China with National Medical Products Administration Approvals
      Oct 7Yahoo FinanceQTRX
      /C O R R E C T I O N -- ALZpath, Inc./

      ALZpath, Inc., a leader in blood test-based diagnostic solutions for Alzheimer's disease, today announced the expansion of its licensing agreement with Quanterix Corporation. The expanded agreement broadens the use of ALZpath's proprietary pTau217 antibody technology on Quanterix's Simoa® research platform, supporting continued innovation as the field advances toward increasingly precise blood-based approaches to understanding Alzheimer's disease pathology.

      Oct 7Yahoo FinanceQTRX
      Quanterix Delivers on Spatial Biology Content Innovation Commitments at ESSB 2026

      BILLERICA, Mass., September 25, 2026--Quanterix Corporation (NASDAQ: QTRX) today reported significant progress on the Content Innovation Engine it introduced at the American Association for Cancer Research (AACR) Annual Meeting 2026, highlighting new updates at the European Society for Spatial Biology (ESSB) September 28-October 1, 2026. This progress underscores Quanterix's growing leadership in spatial biology content, delivering the assays researchers need to do more pivotal work. Built on th

      Sep 25Yahoo FinanceQTRX
      Quanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      BILLERICA, Mass., September 17, 2026--Quanterix Corporation (NASDAQ: QTRX), a global leader in precision biomarker science, today announced that on September 15, 2026, inducement grants (the "Inducement Grants") were made to James Gute, the recently appointed Chief Commercial Officer of the Company, and two other employees in connection with the commencement of their employment. The Inducement Grant to Mr. Gute consisted of 260,315 restricted stock Units ("RSUs") representing 260,315 shares of Q

      Sep 17Yahoo FinanceQTRX
      Quanterix appoints Yuri Fesko as chief medical officer
      Sep 14Investing.comQTRX
      Quanterix Names Dr. Yuri Fesko Chief Medical Officer

      BILLERICA, Mass., September 14, 2026--Quanterix Corporation (Nasdaq: QTRX), a global leader in precision biomarker science, today announced that accomplished physician executive Dr. Yuri Fesko has been appointed Chief Medical Officer of the company. In this new role, he will provide medical and clinical leadership across Quanterix, partnering closely with the company’s Diagnostics, Scientific, R&D, Regulatory, and Commercial teams, to advance Quanterix’s innovative technologies and applications.

      Sep 14Yahoo FinanceQTRX

      This is the newest page. Registered accounts read further back.